Safe Harbor Statement
This press release includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risk and uncertainties that could cause actual results to differ materially from those anticipated. Such statements may relate to Cimatron's plans, objectives and expected financial and operating results. The words "may," "could," "would," "will," "believe," "anticipate," "estimate," "expect," "intend," "plan," and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Cimatron's ability to control. The risks and uncertainties that may affect forward looking statements include, but are not limited to: currency fluctuations, global economic and political conditions, marketing demand for Cimatron products and services, long sales cycles, new product development, assimilating future acquisitions, maintaining relationships with customers and partners, and increased competition. For more details about the risks and uncertainties related to Cimatron's business, refer to Cimatron's filings with the Securities and Exchange Commission. Cimatron cannot assess the impact of or the extent to which any single factor or risk, or combination of them, may cause. Cimatron undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
Company Contact: |
Investor Relations contact |
Ilan Erez, Chief Financial Officer |
Ehud Helft/Kenny Green |
Cimatron Ltd. |
GK Investor Relations |
Tel.; 972-73-237-0114 |
Tel: (US) 1 646 201 9246 |
Email: ilane@cimatron.com |
Email: Cimatron@gkir.com |
CIMATRON LIMITED | ||||||||
CONSOLIDATED STATEMENTS OF INCOME | ||||||||
(US Dollars in thousands, except for per share data) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended | ||
|
|
|
|
|
|
March 31, | ||
|
|
|
|
|
|
2014 |
|
2013 |
|
|
|
|
|
|
|
|
|
Total revenue |
10,963 |
|
10,158 | |||||
|
|
|
|
|
|
|
|
|
Total cost of revenue |
1,503 |
|
1,326 | |||||
|
|
|
|
|
|
|
|
|
Gross profit |
9,460 |
|
8,832 | |||||
|
|
|
|
|
|
|
|
|
Research and development expenses |
1,915 |
|
1,728 | |||||
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
6,474 |
|
6,326 | |||||
Operating income |
1,071 |
|
778 | |||||
|
|
|
|
|
|
|
|
|
Financial income (expenses), net |
(39) |
|
16 | |||||
|
|
|
|
|
|
|
|
|
Taxes on income |
(350) |
|
(192) | |||||
|
|
|
|
|
|
|
|
|
Other |
|
(21) |
|
2 | ||||
|
|
|
|
|
|
|
|
|
Net income |
661 |
|
604 | |||||
|
|
|
|
|
|
|
|
|
Less: Net income attributable to the noncontrolling interest |
(10) |
|
- | |||||
|
|
|
|
|
|
|
|
|
Net income attributable to Cimatron's shareholders |
$ 651 |
|
$ 604 | |||||
Net income per share - basic and diluted |
$ 0.06 |
|
$ 0.06 | |||||
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
Basic EPS (in thousands) |
10,731 |
|
9,348 | ||||
|
|
|
|
|
|
|
|
|
|
Diluted EPS (in thousands) |
10,731 |
|
9,358 |